OA: (ARID1A/ATRi) Gene test could pinpoint patients sensitive to new type of cancer drug Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, December 23, 2016

OA: (ARID1A/ATRi) Gene test could pinpoint patients sensitive to new type of cancer drug



Medical News 

 open access article: ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A, Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeff Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth & Christopher J. Lord, Nature Communications, doi: 10.1038/ncomms13837, published online 13 December 2016.

 Discussion
Our data suggest that ATRi could have potential as single-agent treatments for ARID1A defective cancers. The highly recurrent nature of ARID1A mutations in human cancer and the availability of clinical ATRi suggests that once Phase I clinical trials are complete, biomarker driven proof-of-concept trials could be instigated to assess this hypothesis. These trials could be conducted in cancer types where there is a high frequency of ARID1A mutations, such as OCCC.....

0 comments :

Post a Comment

Your comments?